Want to join the conversation?
Jason Mills of Canaccord asks about the market dynamics with respect to AngioVac. $ANGO CEO Jim Clemmer replied that there is not really a competitive offering from a product standpoint that can do what this product does. He added that the challenge for the company is just making sure it is going to market in a proper way.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.